New insulin injection into the belly could speed up diabetes treatment
NCT ID NCT07341373
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new insulin formula (U-500) given directly into the belly cavity in 25 adults with type 1 diabetes. Researchers want to see if it's safe, how fast it's absorbed, and how quickly it works compared to standard insulin shots. Participants will have their blood sugar kept stable for 12 hours after a single dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Portal Insulin U-500 (PI-U500)
What this could lead to
If successful, this could lead to a faster-acting insulin delivery method for people with type 1 diabetes, potentially improving blood sugar control.
What could go wrong
This is an early Phase 1 safety study with only 25 participants, so results may not apply broadly. The intraperitoneal route carries risks like infection or pain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ProSciento, Inc.
RECRUITINGChula Vista, California, 91911, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••